Screening For B-19 Virus Should Be Limited To Plasma Products - BPAC
This article was originally published in The Gray Sheet
Executive Summary
FDA should not require blood product manufacturers to conduct clinical effectiveness studies or require an investigational new drug exemption for the nucleic acid testing (NAT) of plasma for Parvovirus B-19, members of the agency's Blood Products Advisory Committee agreed at their Sept. 16 meeting in Bethesda, Maryland.